SYROS PHARMACEUTICALS INC's ticker is SYRS and the CUSIP is 87184Q107. A total of 95 filers reported holding SYROS PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.46 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $93,000 | +322.7% | 96,651 | +418.6% | 0.00% | – |
| Q1 2022 | $22,000 | -85.0% | 18,636 | -5.2% | 0.00% | – |
| Q1 2021 | $147,000 | -49.7% | 19,668 | -26.9% | 0.00% | -100.0% |
| Q4 2020 | $292,000 | -28.8% | 26,897 | -41.9% | 0.00% | 0.0% |
| Q3 2020 | $410,000 | -1.7% | 46,331 | +18.4% | 0.00% | 0.0% |
| Q2 2020 | $417,000 | +379.3% | 39,128 | +167.5% | 0.00% | – |
| Q1 2020 | $87,000 | – | 14,629 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 3,139,895 | $23,486,000 | 4.50% |
| Samsara BioCapital, LLC | 2,189,199 | $14,769,000 | 2.72% |
| Bain Capital Life Sciences Investors, LLC | 5,785,036 | $43,272,000 | 2.45% |
| Omega Fund Management, LLC | 1,562,500 | $11,688,000 | 1.11% |
| Flagship Pioneering Inc. | 2,938,494 | $21,980,000 | 0.35% |
| EcoR1 Capital, LLC | 1,000,000 | $7,480,000 | 0.33% |
| Altium Capital Management LP | 126,702 | $948,000 | 0.26% |
| Nikko Asset Management Americas, Inc. | 5,042,009 | $37,714,000 | 0.18% |
| Artal Group S.A. | 1,025,000 | $7,667,000 | 0.14% |
| Orbimed Advisors | 1,837,500 | $13,745,000 | 0.13% |